看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。( z4 u: v4 y& l% W; D9 A
5 }1 l# Y+ a: M8 ^( ^5 c& m
" t- f3 y ~+ W# S
Currently available feasibility data for possible combination strategies.
$ M: {. ?1 O) [: a————————————————————————————————, n% v' P0 v% Z, a5 n
Combination Feasibility according to preliminary data . N1 i6 Q# ]& y0 V8 k1 L1 s2 [
——————————————————————————————————
1 r) U4 {+ g9 Y: S) S% v3 n! z6 c3 \Bevacizumab + sorafenib Yes, reduced dose
! r9 w. S/ L; i) W2 Y1 ~6 uBevacizumab + sunitinib† No ; N) ]& \$ \. c
Bevacizumab + temsirolimus Yes # \' |! h! F+ ~2 L% ^) O5 F1 h& T
Bevacizumab + everolimus Yes ~1 @1 a2 N) l
Sorafenib + sunitinib ?
2 a$ _, L2 x$ dSorafenib + temsirolimus Yes, reduced dose
+ j. E6 k& s, T! ]; |9 C( u) tSorafenib + everolimus Yes, reduced dose ; H/ W, t* s! ]8 A
Sunitinib + temsirolimus† No ( ?+ j& B, A# l- \9 G1 ]
Sunitinib + everolimus ?
- Y/ s9 T2 S& c7 MTemsirolimus + everolimus ?
4 |, R8 c y/ H( n: |6 _& V————————————————————
( r: X+ ]2 I5 g d†Led to US FDA warning.
: D* j5 D/ A+ [! f8 r- p, T?: As yet unattempted combination.8 V6 a$ l8 _) d' y; ^+ q
|